Process development focused on quality control (QC) & regulatory compliance - combined with custom closed loop and automated systems - integrated into standardized mobile processing units.
Regional POCare™ centers, enabling flexible localization of processing units which minimize logistic complexity and enables expedited scale out.
Minimized manual processing steps and isolated processing units enable parallel processing in a low-cost GMP mobile unit. Decentralized POCare™ platform enables reduction of logistic costs.
Orgenesis offers cost-effective scalable manufacturing capacities. The POCare™ platform is a unique globally harmonized and decentralized CGT manufacturing infrastructure and offers cost-effective manufacturing capacities with ease for scalability and reproducibility. Watch the video to learn more.Watch Video
The POCare™ Platform overcomes conventional processing challenges by enabling high quality standards, sterile, scalable onsite processing of CGTs orchestrated by the POCare™ centers, servicing local hospitals and other customers. Manufacturing infrastructure is easily harmonized and reproducible using the OMPUL™, Orgenesis Mobile Processing Unit and Lab technology. It shortens implementation time from 18-24 to 3-6 months, offers a more cost-effective environment and enables local scalability by connecting additional OMPUL™.
Through Global Quality Harmonization standards aimed at ensuring quality comparability across the network and application of good practices (GxP) across all activities and throughout therapy lifecycles.
Where we develop and supply
Cell and gene therapies (CGTs) use modified cells or cellular matter to treat, prevent or cure serious health issues like cancer, genetic disorders, immunodeficiencies, rare diseases, and more.
CGTs have shown potential to replace damaged cells with functional alternatives or to elicit a desired immune response. Despite this great potential, CGTs have proven complex, expensive, and challenging to bring to market, in part because of the logistic hurdles associated with many of these personalized therapies.
Our POCare™ Platform is shaping a CGT ecosystem to lower costs for innovators, accelerate treatments to market, and expand access for patients.